Healthcare provider profile · identity verified

Tanveer Sobhan, MD

Psychiatry · TAMARAC, FL · NPI 1780726836

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Trazodone Hcl	Trazodone Hcl	1188	161
Alprazolam	Alprazolam	1159	125
Quetiapine Fumarate	Quetiapine Fumarate	955	117
Clonazepam	Clonazepam	727	97
Escitalopram Oxalate	Escitalopram Oxalate	683	94
Sertraline Hcl	Sertraline Hcl	623	86
Buspirone Hcl	Buspirone Hcl	612	82
Zolpidem Tartrate	Zolpidem Tartrate	592	73
Duloxetine Hcl	Duloxetine Hcl	546	70
Risperidone	Risperidone	529	55
Mirtazapine	Mirtazapine	521	82
Bupropion Xl	Bupropion Hcl	480	64
Benztropine Mesylate	Benztropine Mesylate	428	50
Aripiprazole	Aripiprazole	426	67
Venlafaxine Hcl Er	Venlafaxine Hcl	416	44
Fluoxetine Hcl	Fluoxetine Hcl	399	48
Lamotrigine	Lamotrigine	374	47
Lorazepam	Lorazepam	336	46
Olanzapine	Olanzapine	321	40
Paroxetine Hcl	Paroxetine Hcl	264	33
Doxepin Hcl	Doxepin Hcl	261	31
Topiramate	Topiramate	222	27
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	213	26
Divalproex Sodium	Divalproex Sodium	203	28
Oxcarbazepine	Oxcarbazepine	200	23
Citalopram Hbr	Citalopram Hydrobromide	198	24
Temazepam	Temazepam	183	23
Hydroxyzine Hcl	Hydroxyzine Hcl	181	39
Lithium Carbonate	Lithium Carbonate	162	17
Hydroxyzine Pamoate	Hydroxyzine Pamoate	158	29
Divalproex Sodium Er	Divalproex Sodium	153	23
Haloperidol	Haloperidol	119	19
Lurasidone Hcl	Lurasidone Hcl	115	13
Bupropion Hcl Sr	Bupropion Hcl	105	19
Propranolol Hcl	Propranolol Hcl	104	17
Prazosin Hcl	Prazosin Hcl	101	13
Eszopiclone	Eszopiclone	93	15
Ziprasidone Hcl	Ziprasidone Hcl	86	11
Dextroamphetamine-Amphet Er	Dextroamphetamine/Amphetamine	79	suppressed
Clonidine Hcl	Clonidine Hcl	77	suppressed
Bupropion Hcl	Bupropion Hcl	67	15
Diazepam	Diazepam	67	suppressed
Gabapentin	Gabapentin	65	15
Clozapine	Clozapine	59	suppressed
Chlorpromazine Hcl	Chlorpromazine Hcl	58	suppressed
Lithium Carbonate Er	Lithium Carbonate	56	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	55	14
Fluphenazine Hcl	Fluphenazine Hcl	51	suppressed
Invega Sustenna	Paliperidone Palmitate	51	suppressed
Atomoxetine Hcl	Atomoxetine Hcl	49	suppressed
Ropinirole Hcl	Ropinirole Hcl	44	suppressed
Paliperidone Er	Paliperidone	40	suppressed
Quetiapine Fumarate Er	Quetiapine Fumarate	40	suppressed
Trihexyphenidyl Hcl	Trihexyphenidyl Hcl	36	suppressed
Carbamazepine Er	Carbamazepine	35	suppressed
Donepezil Hcl	Donepezil Hcl	35	12
Fluvoxamine Maleate	Fluvoxamine Maleate	34	suppressed
Haloperidol Decanoate	Haloperidol Decanoate	32	suppressed
Desvenlafaxine Succinate Er	Desvenlafaxine Succinate	28	suppressed
Vraylar	Cariprazine Hcl	27	suppressed
Perphenazine	Perphenazine	25	suppressed
Belsomra	Suvorexant	24	suppressed
Adderall Xr	Dextroamphetamine/Amphetamine	23	suppressed
Valproic Acid	Valproic Acid (As Sodium Salt)	20	suppressed
Austedo	Deutetrabenazine	19	suppressed
Clomipramine Hcl	Clomipramine Hcl	19	suppressed
Fluphenazine Decanoate	Fluphenazine Decanoate	19	suppressed
Lisdexamfetamine Dimesylate	Lisdexamfetamine Dimesylate	18	suppressed
Vyvanse	Lisdexamfetamine Dimesylate	18	suppressed
Memantine Hcl	Memantine Hcl	17	suppressed
Risperdal Consta	Risperidone Microspheres	17	suppressed
Abilify Maintena	Aripiprazole	15	suppressed
Asenapine Maleate	Asenapine Maleate	15	suppressed
Ingrezza	Valbenazine Tosylate	15	suppressed
Rexulti	Brexpiprazole	15	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	15	suppressed
Guanfacine Hcl Er	Guanfacine Hcl	13	suppressed
Invega	Paliperidone	13	suppressed
Trintellix	Vortioxetine Hydrobromide	12	suppressed
Fanapt	Iloperidone	11	suppressed
Methylphenidate Hcl	Methylphenidate Hcl	11	suppressed
Thiothixene	Thiothixene	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error